Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TIMOTHY LEE SCHOONOVER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1033111802
CMS profile
92344
Location
CENTERVILLE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$92,319.62

264 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 6; records 101–150 of 264 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TIMOTHY LEE SCHOONOVER

NPI 1033111802 · CMS profile ID 92344

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CENTERVILLE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 264 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033111802?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TIMOTHY LEE SCHOONOVER, NPI 1033111802, CMS profile ID 92344. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 264 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033111802?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). TIMOTHY LEE SCHOONOVER, NPI 1033111802, CMS profile ID 92344. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 264 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033111802?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
TIMOTHY LEE SCHOONOVER, NPI 1033111802, CMS profile ID 92344, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 264 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1033111802?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

264 matching records · $92,319.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 264 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 264.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $14.2408/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825840449 CMS
AbbVie Inc. $2,400.0008/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795990003 CMS
AbbVie Inc. $13.9208/17/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795990005 CMS
AbbVie Inc. $21.0708/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795990007 CMS
Allergan, Inc. $9.4208/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792935621 CMS
Neurelis, Inc. $14.4908/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842878975 CMS
UCB, Inc. $16.6108/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807392713 CMS
AbbVie Inc. $2,400.0008/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795989999 CMS
AbbVie Inc. $124.6808/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795990001 CMS
EMD Serono, Inc. $23.4408/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849204677 CMS
GENZYME CORPORATION $14.7308/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843451259 CMS
Alexion Pharmaceuticals, Inc. $17.0208/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783124811 CMS
Novartis Pharmaceuticals Corporation $6.9508/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813237993 CMS
UCB, Inc. $13.0008/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807383467 CMS
Allergan, Inc. $3,840.0008/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792935619 CMS
AbbVie Inc. $3.5908/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795989997 CMS
Amgen Inc. $13.2908/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825840445 CMS
Allergan, Inc. $9.9008/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792935617 CMS
Amgen Inc. $11.9407/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825840441 CMS
EMD Serono, Inc. $25.0807/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849204729 CMS
Novartis Pharmaceuticals Corporation $8.9907/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813237989 CMS
Novartis Pharmaceuticals Corporation $9.3207/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813237985 CMS
Amgen Inc. $450.0007/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825840457 CMS
Amgen Inc. $50.4807/16/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825840465 CMS
Amgen Inc. $2,700.0007/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825840477 CMS
Biogen, Inc. $24.4107/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827861589 CMS
Amgen Inc. $113.3407/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825840489 CMS
Biogen, Inc. $13.3707/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827861591 CMS
Allergan, Inc. $11.4107/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792935615 CMS
Janssen Pharmaceuticals, Inc $26.0507/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788952587 CMS
Neurocrine Biosciences, Inc. $13.6707/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837815145 CMS
Novartis Pharmaceuticals Corporation $4.6807/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813237981 CMS
AbbVie Inc. $10.4507/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795989995 CMS
Amgen Inc. $450.0007/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825840453 CMS
Amgen Inc. $2,700.0007/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825840473 CMS
Amgen Inc. $6.2806/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825840437 CMS
Amgen Inc. $93.3006/30/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825840461 CMS
Novartis Pharmaceuticals Corporation $7.8106/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813237977 CMS
Teva Pharmaceuticals USA, Inc. $10.3306/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839453437 CMS
Alexion Pharmaceuticals, Inc. $14.6206/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783124777 CMS
Allergan, Inc. $11.6406/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792935613 CMS
Biohaven Pharmaceuticals, Inc. $23.6006/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852617319 CMS
Amgen Inc. $95.8106/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825840485 CMS
EMD Serono, Inc. $19.9606/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849198703 CMS
Greenwich Biosciences, Inc. $13.8406/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841849977 CMS
Novartis Pharmaceuticals Corporation $6.7506/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813237973 CMS
AbbVie Inc. $13.9906/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795989993 CMS
AbbVie Inc. $108.0906/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795989987 CMS
AbbVie Inc. $2,400.0006/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795989989 CMS
AbbVie Inc. $16.6706/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795989991 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $101,745.37 320
PY2020 $44,687.46 162
PY2021 $92,319.62 264
PY2022 $60,703.82 242
PY2023 $26,694.18 164
PY2024 $20,550.78 170
PY2025 $40,068.60 189

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $9,446.00 19
PY2024 Principal investigator $22,350.00 6
PY2023 Principal investigator $26,847.08 16
PY2022 Recipient $258.00 1
PY2022 Principal investigator $50,679.07 35
PY2021 Recipient $4,994.00 1
PY2021 Principal investigator $37,752.96 30
PY2020 Principal investigator $50,597.00 2
PY2019 Principal investigator $26,510.64 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.00 09/24/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184242465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $220.00 07/25/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184220260
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $800.00 07/25/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184220262
Principal investigator 1 Eli Lilly and Company $547.00 07/10/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) No dispute reported 06/30/2026 1187877831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.00 06/20/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184209446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.00 06/20/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184209458
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $800.00 06/20/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184209758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.00 06/20/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210038
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.00 06/20/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210044
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 05/28/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184200143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $131.25 05/28/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184200145
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.00 05/28/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184200147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $620.00 04/23/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184185961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $650.00 04/23/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184185963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $800.00 04/23/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184185965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 04/23/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184185967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 04/23/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184185969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $650.00 04/23/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184185971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,347.75 04/23/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184185973

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2019 Amount invested $55,003.67 1
PY2019 Value of interest $83,165.09 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

1 record · PY2019

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2019 Renovis Surgical Technologies, Inc. $55,003.67 $83,165.09 Private Ownership in C-Corp. Physician Covered Recipient No dispute reported 06/30/2026 692904317